Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Slides:



Advertisements
Similar presentations
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Trial profile Fox K et al. Lancet 2008;372:
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.
Randomized, double-blind, multicenter, controlled trial.
Clinical Outcomes with Newer Antihyperglycemic Agents
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Clinical Outcomes with Newer Antihyperglycemic Agents
Discontinuation of medication after nonfatal event: MI
Clinical Outcomes with Newer Antihyperglycemic Agents
The SPRINT Research Group
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study
LEADER trial: Primary Outcome
Clinical need for determination of vulnerable plaques
Copyright © 2007 American Medical Association. All rights reserved.
New Insights from EXSCEL
TNT: Baseline and final LDL cholesterol levels
on behalf of the LEADER Trial Steering Committee and Investigators
Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease  Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,
Baseline characteristics of patients
TNT Study: Baseline Characteristics of the Patients
Study Design Ketil Lunde, et al. N Engl J Med 2006;355:
Fellström BC, et al. N Engl J Med 2009;360:1455-7
Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease  Scott E. Musicant, MD,
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
(p for noninferiority < 0.001)
Svend A. Mortensen et al. JCHF 2014;2:
Enrollment and Outcomes
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Berger JS, et al. JAMA 2009;301:
Characteristics of the Patients at Baseline*
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
Baseline Characteristics of the Study Participants
Patient Disposition James A. de Lemos et al. JAMA 2004; 292:
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Baseline Characteristics of the Patients – Part I
The ACCORD Study Group. NEJM 2010; Epub March 14
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Baseline Characteristics of the Patients - Part I
The ACCORD Study Group. NEJM 2010; Epub March 14
Comparison of Baseline Characteristics by Primary End Point
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%
Christian Madelaire et al. JCHF 2018;6:
Increase of physical activity over time associated with lower HF risk
Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.
Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.
Presentation transcript:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Characteristics of the Patients at Baseline and Follow-up* Duckworth W, et al. N Engl J Med 2009;360:

Changes in Median Glycated Hemoglobin Levels from Baseline through 78 Months Duckworth W, et al. N Engl J Med 2009;360:

Kaplan–Meier Curves for the Time until the First Occurrence of a Primary or Secondary Outcome Duckworth W, et al. N Engl J Med 2009;360: Panel A shows the time until the first occurrence of a major cardiovascular event (the primary outcome), which was a composite of myocardial infarction, stroke, death from cardiovascular causes, congestive heart failure, surgery for vascular disease, inoperable coronary disease, and amputation for ische mic gangrene, in the standard-therapy group and the intensivetherapy group, with a hazard ratio in the intensive-therapy group of 0.88 (95% confidence interval [CI], 0.74 to 1.05). Panel B shows the time until death from a cardiovascular cause (a component of the primary outcome), with a hazard ratio of 1.32 (95% CI, 0.81 to 2.14). Panel C shows the time until death from any cause (a secondary outcome), with a hazard ratio of 1.07 (95% CI, 0.81 to 1.42).

Hypoglycemic Episodes* Duckworth W, et al. N Engl J Med 2009;360:

Microvascular Outcomes* Duckworth W, et al. N Engl J Med 2009;360:

Time to Primary Event Duckworth W, et al. N Engl J Med 2009;360: Supplementary Appendix

Time to Secondary Cardiovascular Events and Total Mortality Duckworth W, et al. N Engl J Med 2009;360: Supplementary Appendix

Cause of Cardiovascular Death Duckworth W, et al. N Engl J Med 2009;360: Supplementary Appendix

Cause of Death: Neoplasm (Non-cardiovascular) Duckworth W, et al. N Engl J Med 2009;360: Supplementary Appendix

Other Causes of Death (Non-cardiovascular) Duckworth W, et al. N Engl J Med 2009;360: Supplementary Appendix

Reporting of Confirmed SAE at least once during follow-up* Duckworth W, et al. N Engl J Med 2009;360: Supplementary Appendix